Displaying drugs 576 - 600 of 8039 in total
Turoctocog alfa pegol
Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.
Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … Turoctocog alfa pegol is a pegylated version of [turoctocog alfa]. ... During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino ... from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of …
LetibotulinumtoxinA
The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial...
Approved
Matched Description: … treatment of facial spasmodic disorders in the early 1970s. ... The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the ... [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] …
Famciclovir
Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Approved
Investigational
Matched Description: … Famciclovir is a prodrug of penciclovir with higher oral bioavailability. …
Nifedipine
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine.[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer...
Approved
Matched Description: … [A190273] The most popular of the third generation dihydropyridines is [amlodipine]. ... second and third generation dihydropyridines have been developed with slower onsets and longer durations of …
Eflornithine
Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … in the risk of death were observed. ... and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of ... eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of …
Human varicella-zoster immune globulin
Human varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the...
Approved
Matched Description: … Human varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified ... It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and ... 2012 under the name VariZIG to reduce the disease severity in high-risk patients who lack evidence of …
Rilonacept
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... linked to the Fc portion of immunoglobulin G1. ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Ferric derisomaltose
Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … [A190528]
Ferric derisomaltose is a form of iron used in the treatment of iron deficiency. ... support production of erythrocytes, also known as red blood cells. ... This drug is a complex of iron (III) hydroxide and derisomaltose. …
Chlordiazepoxide
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Approved
Illicit
Investigational
Matched Description: … It has also been used in the symptomatic treatment of alcohol withdrawal. …
Ferrous gluconate
Approved
Oprelvekin
Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid...
Approved
Investigational
Matched Description: … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids ... In mice and nonhuman primate studies of animals with moderate and severe myelosuppression, in addition ... animal studies, oprelvekin was also shown to regulate intestinal epithelium growth by enhancing healing of …
Nicergoline
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Conestat alfa
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within...
Approved
Investigational
Matched Description: … Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE. ... of bradykinin. ... The primary function of endogenous C1INH is to regulate the activation of the complement and contact …
Abemaciclib
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for …
Damoctocog alfa pegol
In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational
Matched Description: … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin ... a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of …
Cilazapril
Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and...
Approved
Matched Description: … None of these varieties are available in the United States. ... Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. ... It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Brexucabtagene autoleucel
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse...
Approved
Matched Description: … to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour ... Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified ... Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib …
Crisaborole
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … It is currently under development as topical treatment of psoriasis. ... Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection …
Tapinarof
Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily.[L41845, A248790] Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that...
Approved
Investigational
Matched Description: … Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of ... [A248790] In 1959, it was noticed that _Heterorhabditis_ with a high amount of 3,5-dihydroxy-4-isopropylstilbene …
Galcanezumab
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of...
Approved
Investigational
Matched Description: … migraine and the treatment of episodic cluster headache. ... Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of ... [A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile …
Ivosidenib
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … relapsed of refractory acute myeloid leukemia in adults. ... [A248745]
Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of ... A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of …
Leuprolide
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to...
Approved
Investigational
Matched Description: … Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily ... downstream modulation of both gonadotropin hormone and sex steroid levels. ... Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). …
Nabilone
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Description: … , a class of compounds that act upon endogenous cannabinoid receptors of the body [A32584]. ... psychoactive component of cannabis (marijuana). ... Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers. …
Bromocriptine
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Description: … Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as ... In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological ... well as the treatment of acromegaly. …
Displaying drugs 576 - 600 of 8039 in total